Why Does This Fat Loss Peptide Give You a Tan? Fat Loss Peptides Beyond Ozempic

Off-label prescribing is legal. Physicians do it constantly. Injected himself with experimental tanning drug. He got a tan. He also got a spontaneous erection that lasted 8 hours because the receptor that gives you a tan also controls appetite, also metabolism and arousal, all through the same system. In 1991, a researcher at the University of Arizona injected himself with experimental tanning drug. He got a tan. He also got a spontaneous erection that lasted 8 hours. He had to go to the emergency room. The compound was called melatonin-2, and that embarrassing accident changed the course of pharmaceutical research because the receptor that gives you a tan also controls appetite, also metabolism and arousal, all through the same system. That discovery eventually led to an FDA-approved drug for women's sexual dysfunction, and it opened up a whole category of fat loss research that has nothing to do with Ozempic. Today, we're covering three compounds: melatonin two, tesamorelin, and AOD nine six zero four. Three different mechanisms, three very different levels of evidence, and by the end, you'll know exactly which one has real clinical data, which one is legitimate but incomplete, and which one is being sold to you on a lie about what FDA approvals actually mean. To understand melatonin two, you need to know about one receptor system: the melanocortin system. You have five melanocortin receptors, MC1R through MC5R, each. Each one does something different. MC1R sits in your skin cells. Activate it and your body produces more melanin. More melanin means more pigmentation, a tan. MC4R sits in your brain, in the hypothalamus. Activate it and appetite goes down, energy expenditure goes up. Melatonin 2 activates all 5 receptors at once. That is why the research got a tan and— But also an erection. MC1R gave him the pigmentation. MC4R in a different neural circuit triggers the arousal. Same receptor, different context, different outcome. The appetite suppression through MC4R is real. Animal studies showed significant reductions in food intake and body weight. The mechanism is not a question. But here is a problem with Balaenon-2. It is not yet approved anywhere, including FDA approval. It is sold online as a research chemical with no quality control. The dose on the label may not match what is in the vial. The compound may not even be what they say it is. There are also documented cases of melanoma in users. Activating melanocytes that are already abnormal is not something you want to do. Multiple health agencies have issued warnings. The science is interesting, the safety profile is incomplete, and the supply chain is completely uncontrolled. What actually came out of this research was bremelotinide, a more selective compound, FDA approved in 2019 under the name Velysse for women's sexual dysfunction. That is where the legitimate science landed. Melatonin-2 itself is still in the gray zone. Now, tesamorelin is a different story entirely. This one has real clinical evidence behind it. Tesamorelin is a synthetic version of growth hormone-releasing hormone, GHRH. Your hypothalamus produces GHRH naturally. It tells your pituitary to release growth hormone in pulses. As you age, GHRH production declines, the pulses get smaller, less frequent, growth hormone drops, and visceral fat accumulates. The deep abdominal fat around your organs. Tesamorelin tells the pituitary to release more growth hormone in the natural pulsatile pattern the body already uses. This matters. When people inject exogenous growth hormone, they flood the system continuously. The body does not work that way. GH is supposed to come in pulses. Tesamorelin works with that existing mechanism instead of overriding it. The FDA actually approved it in 2010 under the name Egrifta for HIV-associated Lipodystrophy. That is a condition where antiretroviral drugs cause visceral fat to accumulate as a side effect. The phase 3 trials involve 816 patients. CT confirmed visceral fat reduction of 15 to 18%. Not estimated, not self-reported, imaging confirmed. In March 2025, the FDA approved an updated version, Egrifta WR, a weekly injection instead of daily. Same mechanism. Off-label prescribing is legal. Physicians do it constantly. The mechanistic rationale is solid. The human trial data is real. The side effects, however, are also real. Some documented side effects include fluid retention, joint pain, insulin sensitivity— blood sugar can rise. Anyone with diabetes or prediabetes needs close monitoring. But of those 3 compounds today, this is the one with the most rigorous human evidence. FDA-approved phase 3 data, imaging-confirmed fat reduction, 816 patients. Now the one where the marketing has got completely out ahead of the evidence. AOD-9604, which stands for anti-obesity drug, is a fragment of the growth hormone molecule, specifically the last 16 amino acids on the C-terminal end, the region researchers believe was responsible for growth hormone's fat-burning effects. The idea was elegant: growth hormone builds muscle and burns fat through different parts of the molecule. Isolate just the fat-burning fragment and you get lipolysis, without the anabolic side effects. In animal studies, it looked promising, reducing body fat in obese mice without significantly affecting IGF-1 or glucose. They moved it into human trials. 6 clinical trials were conducted. It failed to meet its primary endpoint in phase 3. The trials could not demonstrate statistically significant fat loss in humans at the doses tested. The company discontinued development, but then something happened in 2014. The FDA granted AOD-9604 GRAS status, generally recognized as safe. This is actually a food additive classification. It means a compound can be used as a food ingredient at the doses reviewed. And the wellness industry took that GRAS status and called it FDA approval. You'll see this everywhere— FDA approved, FDA cleared, FDA recognized— applied to AOD-9604 as a fat loss compound. GRAS is not drug approval. It means the FDA reviewed it as a food additive and said it is safe to eat in food. That is completely different regulatory pathway. And here is what makes it concerning as a peptide weight loss option. The human trials used oral formulations. The injectable form of AOD-9604 being sold right now has never been tested in a human trial. So the compound failed the trials that were run, has food additive status only, and the version people are actually injecting has zero human data. When you see FDA language attached to this compound, it is misrepresentation. Whether intentional or not, the impression it creates is false. So here's where things actually stand. Tesamorelin is the one with real receipts. FDA approved, phase 3 trials, over 800 patients, CT confirmed fat loss, not just before and after photos. If you're going to explore any one of these with a physician, this is the one the evidence supports. Melatonin 2 is fascinating biology that never quite made it across the finish line. The science was real enough that it spun off into FDA approved drug for women's sexual dysfunction, but melatonin 2 itself is still in the gray zone. Unregulated supply, incomplete safety data, and some real concerns around melanocyte. Stimulation. Worth understanding the risk before blindly injecting just because your favorite influencer is using it. AOD-9604 is the one where the marketing got way ahead of the evidence. It failed its human trials. Grass means it's safe to eat in food, not that it works for fat loss. If someone is selling it to you with FDA language attached, they're either confused or hoping that you are. And none of this means peptides are bad. The space is genuinely exciting, and I've personally tried some out and have been happy with my results. Notable mentions in the weight loss space are retatrutride and tirzepatide. Retatrutride is showing remarkable results in early trials, and tirzepatide is already FDA approved and outperforming a lot of what came before it. The science is moving fast, and some of it is genuinely working. The lesson here is just the mechanism alone is not the same as evidence, and knowing the difference is what separates smart use from expensive guesswork. The wellness industry is very good at making the frontier look like it has already arrived. GRAS sounds like approval, and phase 3 failure sounds like a technicality. It is not. Animal data is not human data. GRAS is not approval, and a failed trial is a failed trial. Now you know the difference before you decide to purchase. If this was useful, share it with someone who's considering a weight loss peptide and might not know the intricacies of approval labels. They deserve to know what that actually means. Subscribe if you're new here, and I'll see you in the next one.